Public criticism and scrutiny from lawmakers will likely remain, keeping biotech and pharma under pressure. At the same time, a cooperative FDA and scientific advances in oncology, cell and gene therapy should continue to serve as a tailwind, generating new approvals and investor optimism. Digital opportunities, including in artificial intelligence, have also proved attractive to drugmakers, spurring changes among executive teams. Here are seven trends to watch as 2019 unfolds… Read the full article…
